Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Opicapone and Levodopa/Carbidopa in Healthy Males
NCT02169453Phase 1Completed
- Sponsor
- BIAL
- Start
- Oct 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Area Under the Plasma Concentration-time Curve to Last Measurable Time Point at 72 hours and 4 more. Started Oct 2008; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02169453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169453.